Optimization of interferon-γ cancer gene therapy by regulating transgene expression profile or controlling the tissue distribution of transgene product

Year
2011
Authors
Yoshinobu Takakura, Yuki Takahashi, Yoshihiko Watanabe and Makiya Nishikawa
Institutions
Department of Biopharmaceutics and Drug Metabolism, Department of Molecular Microbiology, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan takakura@pharm.kyoto-u.ac.jp
Summary

New cancer therapeutic system has been developed by utilizing interferon-γ (IFNγ) gene delivery. Plasmid vectors that express IFNγ for a long period of time were constructed. Separately, genetically modified IFNγ fusion proteins were designed to control the tissue distribution of IFNγ. IFNγ fused with mouse serum albumin showed an extended retention in the serum after in vivo gene transfer. These changes in the expression profile or in the tissue distribution were proved effective in increasing the therapeutic potency of IFNγ gene delivery.

join_crs.jpg